17 research outputs found

    Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma

    No full text
    Papillary thyroid carcinoma (PTC) and benign thyroid adenoma (BTA) are the most common head and neck tumors. However, the metabolic differences between PTC and BTA have not been characterized. The aim of this study was to identify the metabolic profiles of these two types of tumors using a metabolomics approach. Tumors and adjacent nontumor specimens collected from 57 patients with PTC and 48 patients with BTA were profiled using gas chromatography–time-of-flight mass spectrometry and ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry. A panel of 46 and 44 differentially expressed metabolites were identified in the PTC and BTA specimens, respetively, and compared with nontumor tissues. Common metabolic signatures, as characterized by increased glycolysis, amino acid metabolism, one carbon metabolism and tryptophan metabolism, were found in both types of tumors. Purine and pyrimidine metabolism was significantly elevated in the PTC specimens, and taurine and hypotaurine levels were also higher in the PTC tissues. Increased fatty acid and bile acid levels were found, especially in the BTA tissues. The metabolic profiles of the PTC and BTA tissues include both similar and remarkably different metabolites, suggesting the presence of common and unique mechanistic pathways in these types of tumors during tumorigenesis

    Tryptophan Predicts the Risk for Future Type 2 Diabetes

    No full text
    <div><p>Recently, 5 amino acids were identified and verified as important metabolites highly associated with type 2 diabetes (T2D) development. This report aims to assess the association of tryptophan with the development of T2D and to evaluate its performance with existing amino acid markers. A total of 213 participants selected from a ten-year longitudinal Shanghai Diabetes Study (SHDS) were examined in two ways: 1) 51 subjects who developed diabetes and 162 individuals who remained metabolically healthy in 10 years; 2) the same 51 future diabetes and 23 strictly matched ones selected from the 162 healthy individuals. Baseline fasting serum tryptophan concentrations were quantitatively measured using ultra-performance liquid chromatography triple quadruple mass spectrometry. First, serum tryptophan level was found significantly higher in future T2D and was positively and independently associated with diabetes onset risk. Patients with higher tryptophan level tended to present higher degree of insulin resistance and secretion, triglyceride and blood pressure. Second, the prediction potential of tryptophan is non-inferior to the 5 existing amino acids. The predictive performance of the combined score improved after taking tryptophan into account. Our findings unveiled the potential of tryptophan as a new marker associated with diabetes risk in Chinese populations. The addition of tryptophan provided complementary value to the existing amino acid predictors.</p></div

    a) Baseline tryptophan levels (mean with S.E.) in future NGT (n = 162), matched future NGT (n = 23), and future T2D (n = 51) groups. b) Association of tryptophan with metabolic markers in all participants (n = 213).

    No full text
    <p><b>Abbreviations:</b> BMI = body mass index; Glucose0 = fasting plasma glucose; Glucose120 = 2 h plasma glucose; INS0 = fasting insulin; INS120 = 2 h insulin; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SP = systolic blood pressure; DP = diastolic blood pressure; TC = total cholesterol; TG = total triglycerides; HOMA-IR = homeostatic model assessment of insulin resistance (FPG*INS0/22.5); Matsuda index = 10000/(Glucose0Ă—INS0Ă—Glucose120Ă—INS120)<sup>0.5</sup>; HOMA-Beta = homeostatic model assessment of beta-cell function (20*INS0/(Glucose0-3.5); First-phase secretion = 2032+4.681*INS0-135*Glucose120+0.995*INS120+27.99*BMI-269.1*Glucose0; Second-phase secretion = 277+0.8*INS0-42.79*Glucose120+0.321*INS120+5.338*BMI.</p
    corecore